Arabic Arabic English English French French German German
dark

Teplizumab Awarded Innovation Passport in the United Kingdom (UK) for the Delay of Onset of Clinical Type 1 Diabetes in At-risk Individuals

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced that teplizumab, an anti-CD3 monoclonal antibody, was awarded an Innovation Passport for the delay of clinical type 1 diabetes in at-risk individuals. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Acutus Medical, Inc. Announces Proposed Public Offering of Common Stock

Next Post

Veteran AI and ML Leader from LG Electronics and Bosch Joins H1 as SVP of Data Science and Machine Learning

Related Posts
Total
0
Share